Supreme Court decision does not bring any clarity to the technical issues at stake, but it does establish clear rules for how judges should handle complex patent suits
A summary of the major IP news from the biotechnology, pharmaceutical and medical technology sectors in November and the first-half of December
The decision in Monsanto’s appeal against the revocation of a key patent right could have profound implications on the ability to protect agro-biotech inventions in India
This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night
How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong
Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one
Life sciences IP is on the front line as American consumers, legislators and the Trump administration kick back against the high cost of medicines. Reform campaigners say they have never been more confident of change.
Justices today considering a much-anticipated case whose outcome could make it harder for pharma companies to obtain such protection in the future
Tipped to be the ranking Republican on the House Judiciary Committee, Doug Collins looks set to emerge as one of most powerful IP policy voices on Capitol Hill
Cannabis patent war looming, “New NAFTA” set to benefit biopharma innovators, a blow for medical device inventors at the CJEU, and much more in this round-up of October’s big life sciences IP news
Company now faces possibility of £500 million pay-out to the NHS, while ruling could also make second medical use patents harder to obtain and easier to invalidate
A split Congress and a USPTO director looking to rebalance the system probably rule out further legislative reform, but pharma may be vulnerable to moves related to pricing issues
At IPBC Australasia in Melbourne, in-house leaders discuss patent reform, doing more with less, and using IP to attract investment.
New edition will be effective from 1st November. As well as software-related topics, it covers issues such as unity of inventions, biological processes and changes to oral and opposition proceedings